Loading...
Reach Banner
Keywords
Last name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Mary Shago and Adam Shlien.

 
Connection Strength
 
 
 
0.559
 
  1. Anderson ND, de Borja R, Young MD, Fuligni F, Rosic A, Roberts ND, Hajjar S, Layeghifard M, Novokmet A, Kowalski PE, Anaka M, Davidson S, Zarrei M, Id Said B, Schreiner LC, Marchand R, Sitter J, Gokgoz N, Brunga L, Graham GT, Fullam A, Pillay N, Toretsky JA, Yoshida A, Shibata T, Metzler M, Somers GR, Scherer SW, Flanagan AM, Campbell PJ, Schiffman JD, Shago M, Alexandrov LB, Wunder JS, Andrulis IL, Malkin D, Behjati S, Shlien A. Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science. 2018 08 31; 361(6405).
    View in: PubMed
    Score: 0.214
  2. Shlien A, Baskin B, Achatz MI, Stavropoulos DJ, Nichols KE, Hudgins L, Morel CF, Adam MP, Zhukova N, Rotin L, Novokmet A, Druker H, Shago M, Ray PN, Hainaut P, Malkin D. A common molecular mechanism underlies two phenotypically distinct 17p13.1 microdeletion syndromes. Am J Hum Genet. 2010 Nov 12; 87(5):631-42.
    View in: PubMed
    Score: 0.125
  3. Tandon S, Shago M, Davidson S, Kanwar N, Fuligni F, Shlien A, Whitlock J, Villani A, Abla O. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia. Cancer Genet. 2020 Oct; 248-249:31-33.
    View in: PubMed
    Score: 0.062
  4. Langenberg-Ververgaert K, Renzi S, Fuligni F, Davidson S, Abdelhaleem M, Lo W, Malkin D, Shlien A, Shago M, Villani A, Abla O. TERT promotor variant associated with poor clinical outcome in a patient with novel RBM15-MKL1 fusion-positive pediatric acute megakaryoblastic leukemia. Pediatr Blood Cancer. 2020 Aug 02; e28542.
    View in: PubMed
    Score: 0.061
  5. Renzi S, Langenberg-Ververgaert K, Fuligni F, Ryan AL, Davidson S, Anderson N, Hayes R, Hopyan S, Gerstle JT, Shago M, Chami R, Malkin D, Shlien A, Villani A, Gupta AA. Aggressive embryonal rhabdomyosarcoma in a 3-month-old boy: A clinical and molecular analysis. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):407-414.
    View in: PubMed
    Score: 0.055
  6. Mistry M, Zhukova N, Merico D, Rakopoulos P, Krishnatry R, Shago M, Stavropoulos J, Alon N, Pole JD, Ray PN, Navickiene V, Mangerel J, Remke M, Buczkowicz P, Ramaswamy V, Guerreiro Stucklin A, Li M, Young EJ, Zhang C, Castelo-Branco P, Bakry D, Laughlin S, Shlien A, Chan J, Ligon KL, Rutka JT, Dirks PB, Taylor MD, Greenberg M, Malkin D, Huang A, Bouffet E, Hawkins CE, Tabori U. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015 Mar 20; 33(9):1015-22.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.